Clene Inc.CLNNEarnings & Financial Report
Clene Inc. is a clinical-stage biopharmaceutical company that develops novel neuroprotective therapeutics to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis, and Parkinson’s disease. It operates primarily in the U.S. market, focusing on advancing its small molecule candidate pipeline through clinical trials to address unmet medical needs.
Revenue
$87.0K
Gross Profit
$69.0K
Operating Profit
$-7.8M
Net Profit
$-8.0M
Gross Margin
79.3%
Operating Margin
-8982.8%
Net Margin
-9179.3%
YoY Growth
-19.4%
EPS
$-1.22
Clene Inc. Q3 FY2024 Financial Summary
Clene Inc. reported revenue of $87.0K (down 19.4% YoY) for Q3 FY2024, with a net profit of $-8.0M (down 230.3% YoY) (-9179.3% margin). Cost of goods sold was $18.0K, operating expenses totaled $7.9M.
Key Financial Metrics
| Total Revenue | $87.0K |
|---|---|
| Net Profit | $-8.0M |
| Gross Margin | 79.3% |
| Operating Margin | -8982.8% |
| Report Period | Q3 FY2024 |
Clene Inc. Annual Revenue by Year
Clene Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $200.0K).
| Year | Annual Revenue |
|---|---|
| 2025 | $200.0K |
| 2024 | $342.0K |
| 2023 | $654.0K |
| 2022 | $473.0K |
Clene Inc. Quarterly Revenue & Net Profit History
Clene Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $77.0K | -15.4% | $-9.2M | -11981.8% |
| Q3 FY2025 | $15.0K | -82.8% | $-8.8M | -58513.3% |
| Q2 FY2025 | $27.0K | -70.3% | $-7.4M | -27477.8% |
| Q1 FY2025 | $81.0K | +11.0% | $-751.0K | -927.2% |
| Q4 FY2024 | $91.0K | -46.5% | $-13.5M | -14889.0% |
| Q3 FY2024 | $87.0K | -19.4% | $-8.0M | -9179.3% |
| Q2 FY2024 | $91.0K | -66.2% | $-6.8M | -7456.0% |
| Q1 FY2024 | $73.0K | -31.8% | $-11.1M | -15178.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $73000 | $91000 | $87000 | $91000 | $81000 | $27000 | $15000 | $77000 |
| YoY Growth | -31.8% | -66.2% | -19.4% | -46.5% | 11.0% | -70.3% | -82.8% | -15.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $45.1M | $40.3M | $31.6M | $27.3M | $25.3M | $22.1M | $22.3M | $18.1M |
| Liabilities | $40.8M | $40.8M | $35.7M | $36.2M | $30.3M | $30.7M | $34.7M | $35.7M |
| Equity | $4.3M | $-504000 | $-4.1M | $-8.9M | $-5.0M | $-8.6M | $-12.4M | $-17.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.1M | $-6.4M | $-3.0M | $-4.9M | $-5.0M | $-4.7M | $-4.0M | $-4.8M |